Literature DB >> 30339386

RuII( p-cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in Vivo.

Oscar A Lenis-Rojas1, M Paula Robalo2,3, Ana Isabel Tomaz4, Andreia Carvalho5, Alexandra R Fernandes5, Fernanda Marques6, Mónica Folgueira7,8, Julián Yáñez7, Digna Vázquez-García1, Margarita López Torres1, Alberto Fernández1, Jesús J Fernández1.   

Abstract

Ruthenium(II) complexes are currently considered a viable alternative to the widely used platinum complexes as efficient anticancer agents. We herein present the synthesis and characterization of half-sandwich ruthenium compounds with the general formula [Ru( p-cymene)(L-N,N)Cl][CF3SO3] (L = 3,6-di-2-pyridyl-1,2,4,5-tetrazine (1) 6,7-dimethyl-2,3-bis(pyridin-2-yl)quinoxaline (2)), which have been synthesized by substitution reactions from the precursor dimer [Ru( p-cymene)(Cl)(μ-Cl)]2 and were characterized by elemental analysis, mass spectrometry, 1H NMR, UV-vis, and IR spectroscopy, conductivity measurements, and cyclic voltammetry. The molecular structure for complex 2 was determined by single-crystal X-ray diffraction. The cytotoxic activity of these compounds was evaluated against human tumor cells, namely ovarian carcinoma A2780 and breast MCF7 and MDAMB231 adenocarcinoma cells, and against normal primary fibroblasts. Whereas the cytotoxic activity of 1 is moderate, IC50 values found for 2 are among the lowest previously reported for Ru( p-cymene) complexes. Both compounds present no cytotoxic effect in normal human primary fibroblasts when they are used at the IC50 concentration in A2780 and MCF7 cancer cells. Their antiproliferative capacity is associated with a combined mechanism of apoptosis and autophagy. A strong interaction with DNA was observed for both with a binding constant value of the same magnitude as that of the classical intercalator [Ru(phen)2(dppz)]2+. Both complexes bind to human serum albumin with moderate to strong affinity, with conditional binding constants (log Kb) of 4.88 for complex 2 and 5.18 for complex 1 in 2% DMSO/10 mM Hepes pH7.0 medium. The acute toxicity was evaluated in zebrafish embryo model using the fish embryo acute toxicity test (FET). Remarkably, our results show that compounds 1 and 2 are not toxic/lethal even at extremely high concentrations. The novel compounds reported herein are highly relevant antitumor metallodrug candidates, given their in vitro cytotoxicity toward cancer cells and the lack of in vivo toxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30339386     DOI: 10.1021/acs.inorgchem.8b01270

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  10 in total

1.  Manganese(I) tricarbonyl complexes as potential anticancer agents.

Authors:  Oscar A Lenis-Rojas; Beatriz Carvalho; Rui Cabral; Margarida Silva; Sofia Friães; Catarina Roma-Rodrigues; Marta S H Meireles; Clara S B Gomes; Jhonathan A A Fernández; Sabela F Vila; Juan A Rubiolo; Laura Sanchez; Pedro V Baptista; Alexandra R Fernandes; Beatriz Royo
Journal:  J Biol Inorg Chem       Date:  2021-10-29       Impact factor: 3.358

Review 2.  Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer's Disease.

Authors:  Shanshan Wang; Xianbo Kong; Zhangjing Chen; Guopin Wang; Juan Zhang; Jing Wang
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

3.  The Synthesis, Characterization, Molecular Docking and In Vitro Antitumor Activity of Benzothiazole Aniline (BTA) Conjugated Metal-Salen Complexes as Non-Platinum Chemotherapeutic Agents.

Authors:  Md Kamrul Islam; Seongmin Ha; Ah-Rum Baek; Byeong-Woo Yang; Yeoun-Hee Kim; Hyun-Jin Park; Minsup Kim; Sung-Wook Nam; Gang-Ho Lee; Yongmin Chang
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-15

4.  Mechanistic study on substitution reaction of a citrato(p-cymene)Ru(ii) complex with sulfur-containing amino acids.

Authors:  Sen-Ichi Aizawa; Kohei Takizawa; Momoko Aitani
Journal:  RSC Adv       Date:  2019-08-13       Impact factor: 4.036

5.  Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity.

Authors:  Bruno Demoro; Andreia Bento-Oliveira; Fernanda Marques; João Costa Pessoa; Lucía Otero; Dinorah Gambino; Rodrigo F M de Almeida; Ana Isabel Tomaz
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

6.  Utilization of Guanidine-Based Ancillary Ligands in Arene-Ruthenium Complexes for Selective Cytotoxicity.

Authors:  Jit Karmakar; Promita Nandy; Saurabh Das; Debalina Bhattacharya; Parimal Karmakar; Samaresh Bhattacharya
Journal:  ACS Omega       Date:  2021-03-19

7.  ATP7B Binds Ruthenium(II) p-Cymene Half-Sandwich Complexes: Role of Steric Hindrance and Ru-I Coordination in Rescuing the Sequestration.

Authors:  Kallol Purkait; Arindam Mukherjee; Arnab Gupta
Journal:  Inorg Chem       Date:  2019-10-28       Impact factor: 5.165

Review 8.  Therapeutic Potential of Volatile Terpenes and Terpenoids from Forests for Inflammatory Diseases.

Authors:  Taejoon Kim; Bokyeong Song; Kyoung Sang Cho; Im-Soon Lee
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

9.  p-Cymene Complexes of Ruthenium(II) as Antitumor Agents.

Authors:  María Angeles Pujante-Galián; Sergio A Pérez; Mercedes G Montalbán; Guzmán Carissimi; Marta G Fuster; Gloria Víllora; Gabriel García
Journal:  Molecules       Date:  2020-10-31       Impact factor: 4.411

10.  pH-Responsive Release of Ruthenium Metallotherapeutics from Mesoporous Silica-Based Nanocarriers.

Authors:  Minja Mladenović; Ibrahim Morgan; Nebojša Ilić; Mohamad Saoud; Marija V Pergal; Goran N Kaluđerović; Nikola Ž Knežević
Journal:  Pharmaceutics       Date:  2021-03-28       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.